Skip to main content
  1. Life
  2. Health & Fitness
  3. Holistic Health

Dermal Regeneration for the Treatment of Diabetic Foot Ulcers

See also

Integra LifeSciences Holdings Corporation has announced the enrollment of 307 patients for ramdomized controlled clinical trial comparing the safety and effectiveness of
Integra(R) Dermal Regeneration Template, “an advanced bilayer skin replacement system designed to provide immediate wound closure and permanent skin regeneration, against standard of care for the treatment of diabetic foot ulcers.

Integra LifeSciences specializes in developing treatments for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

"Integra Dermal Regeneration Template has a long clinical history of success in burns and scar contracture release, and has the potential to help many people who are suffering with diabetic foot ulcers," stated lead clinical investigator Dr. Vickie Drive. "I look forward to seeing the results from the study, and am hopeful that we will have a new therapy to treat patients with difficult-to-heal wounds."

It is now estimated that 25% of the current 26 million people with diabetes in the US may suffer from disease related foot ulcers at some time during their lifetime. Diabetic foot ulcer is a major complication of diabetes mellitus, and is oftenj a precursor to 84% of allamputations of the lower leg due to the development of macro and micro vascular complications, including failure of the wounds to heal.

"Completion of patient enrollment in the Integra Dermal Regeneration Template diabetic foot ulcer clinical trial is a major milestone for Integra, and marks an important first step toward product commercialization," said Robert D. Paltridge, President, Extremity Reconstruction. "We hope to use the results from this study to receive the expanded indication, which will allow us to provide an additional treatment option to address the increasing prevalence of diabetic foot
ulcers. We look forward to being able to better serve our customers and the diabetic population by providing clinically relevant, cost effective solutions."

The trials will take place at 32 sites, and all patients are followed for up to 28 weeks. Once patient follow-up is complete, this data will be sent to the FDA for eventual product approval.

Advertisement

Life

  • Transgender cop
    A transgender police officer is stepping down from her position to run for office
    Video
    Political Office
  • Easter eggs
    Craft delicate, hand-painted eggs with flowers and other designs celebrating spring
    Camera
    Easter Eggs
  • Subway message
    Subway customer finds 'Big Mama' written on her order
    Video
    Subway Message
  • Working from home
    Working from home can be an exciting venture. Get tips to ensure productivity
    Camera
    Get Tips
  • Limes
    Rising cost of limes could be putting the squeeze on your favorite restaurant
    Expensive Limes
  • Pope Francis
    Religion: Pope Francis instructs how to fight against Satan
    Morning Mass

User login

Log in
Sign in with your email and password. Or reset your password.
Write for us
Interested in becoming an Examiner and sharing your experience and passion? We're always looking for quality writers. Find out more about Examiner.com and apply today!